Hypera (OTCMKTS:HYPMY) Releases Earnings Results

Hypera (OTCMKTS:HYPMY) issued its earnings results on Thursday. The company reported $0.02 EPS for the quarter, Zacks reports. Hypera had a return on equity of 13.18% and a net margin of 20.04%.

Hypera Stock Up 4.7 %

Shares of OTCMKTS:HYPMY opened at $3.62 on Friday. Hypera has a 52-week low of $2.64 and a 52-week high of $6.90. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.68. The company has a fifty day moving average of $3.27 and a 200-day moving average of $3.74.

Hypera Company Profile

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, Max Sulid, milgamma, Mioflex A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, Pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.